MB-CART20.1

BIOLOGICAL4 trials

Conditions

Acute Lymphatic LeukemiaB-cell Lymphoma RecurrentB-cell Lymphoma RefractoryB-cell Non Hodgkin LymphomaChildhood Non-Hodgkin LymphomaChronic Lymphatic LeukemiaMelanoma (Skin)Melanoma Stage III

Early Phase 1

MB-CART20.1 Melanoma

TerminatedNCT03893019

Miltenyi Biomedicine GmbHMelanoma (Skin)

Start: 2019-03-08End: 2023-01-30Updated: 2024-05-16

Phase 1

MB-CART20.1 Lymphoma

CompletedNCT03664635

Miltenyi Biomedicine GmbHB-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Non-Hodgkin's Lymphoma +1

Start: 2018-09-25End: 2024-09-17Updated: 2024-11-21

Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies

RecruitingCTIS2022-501648-14-00

Miltenyi Biomedicine GmbHadult NHL/chronic lymphatic leukemia [CLL]), aggressive NHL), Relapsed or refractory B cell non-Hodgkins lymphoma (NHL) +4

Start: 2024-05-05Target: 40Updated: 2025-07-18

Unknown Phase

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

RecruitingNCT06508775

Miltenyi Biomedicine GmbHAcute Lymphatic Leukemia, B-cell Non Hodgkin Lymphoma, Childhood Non-Hodgkin Lymphoma +4

Start: 2024-05-05End: 2040-12-31Target: 40Updated: 2025-11-26

Related Papers

Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma